0001479290-23-000012.txt : 20230123
0001479290-23-000012.hdr.sgml : 20230123
20230123173536
ACCESSION NUMBER: 0001479290-23-000012
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230120
FILED AS OF DATE: 20230123
DATE AS OF CHANGE: 20230123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schilke Tobin
CENTRAL INDEX KEY: 0001678984
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36297
FILM NUMBER: 23545362
MAIL ADDRESS:
STREET 1: 7000 SHORELINE COURT, #371
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Revance Therapeutics, Inc.
CENTRAL INDEX KEY: 0001479290
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770551645
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1222 DEMONBREUN STREET
STREET 2: SUITE 2000
CITY: NASHVILLE
STATE: TN
ZIP: 37203
BUSINESS PHONE: 6157247755
MAIL ADDRESS:
STREET 1: 1222 DEMONBREUN STREET
STREET 2: SUITE 2000
CITY: NASHVILLE
STATE: TN
ZIP: 37203
4
1
wf-form4_167451332217569.xml
FORM 4
X0306
4
2023-01-20
0
0001479290
Revance Therapeutics, Inc.
RVNC
0001678984
Schilke Tobin
C/O REVANCE THERAPEUTICS, INC.
1222 DEMONBREUN STREET, 20TH FLOOR
NASHVILLE
TN
37203
0
1
0
0
CFO
Common Stock
2023-01-20
4
S
0
1000
31
D
57877
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke.
Includes 3,716 shares purchased pursuant to the Issuer's 2014 Employee Stock Purchase Plan.
/s/ Dwight Moxie, Attorney-in-Fact
2023-01-23